MedGenome vs Tempus

Tempus has a disclosed valuation of $8.1B, while MedGenome's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to MedGenome's $264M — a gap of $786M. Combined, the two companies have completed 11 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while MedGenome sits at 63/100. That 21-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

MedGenome was founded by Sam Santhosh in 2013. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

MedGenome got there first, launching in 2013 — that's 2 years of extra runway. Tempus didn't arrive until 2015. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

MedGenome has about 200-500 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both MedGenome and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.